Horizon Pharma plc to Participate in the UBS Global Healthcare Conference
May 01, 2018 08:00 ET
|
Horizon Pharma plc
DUBLIN, IRELAND, May 01, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), today announced that the company will participate in the following conference in May: UBS Global Healthcare...
Horizon Pharma plc Named No. 1 Biopharma Company to Work for by Great Place to Work® and FORTUNE
April 12, 2018 16:30 ET
|
Horizon Pharma plc
- Company also awarded “Best Places to Work in Chicago” and “10 Best Places to Work for Women” by Crain’s Chicago Business - DUBLIN, Ireland, April 12, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma...
Horizon Pharma plc to Release First-Quarter 2018 Financial Results and Host Webcast on May 9, 2018
April 09, 2018 08:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, April 09, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP) announced today that its first-quarter financial results will be released on Wednesday, May 9, 2018. Following...
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 04, 2018 08:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, April 04, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on Apr. 1, 2018 of...
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
March 06, 2018 16:05 ET
|
Horizon Pharma plc
DUBLIN, Ireland, March 06, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on Mar. 1, 2018 of...
Horizon Pharma plc Announces Fourth-Quarter and Full-Year 2017 Results
February 28, 2018 07:00 ET
|
Horizon Pharma plc
-- Fourth-Quarter 2017 Net Sales of $274.2 Million;Fourth-Quarter 2017 Net Loss of $46.4 Million; Adjusted EBITDA of $102.7 Million -- -- Fourth-Quarter 2017 Operating Cash Flow of $143.2 Million;...
Horizon Pharma plc Submits Supplemental New Drug Application for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to Expand Age Range to Include Newborns
February 27, 2018 18:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that it has submitted a supplemental New Drug Application (sNDA) with the U.S. Food and Drug...
Horizon Pharma Gift Establishes First Clinical Team Endowment at Children’s National Rare Disease Institute
February 26, 2018 08:00 ET
|
Horizon Pharma plc
WASHINGTON, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Children’s National Health System and Horizon Pharma plc are pleased to announce the creation of the Horizon Pharma Clinical Care Endowment, the first...
Horizon Pharma plc to Participate in the Cowen and Company 38th Annual Health Care Conference
February 26, 2018 07:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the company will present at the following conference in March: Cowen and Company 38th Annual...
Horizon Pharma plc Announces Release of the First RAREis™ Song in Partnership with Sing Me a Story Foundation and Global Genes
February 22, 2018 09:00 ET
|
Horizon Pharma plc
-- Yearlong partnership will create 20 songs from the stories of children living with rare diseases – -- Downloads of each RAREis song in 2018 will benefit the patient organization supporting the...